Oramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -0.43% | -3.77% | -0.43% |
15/05 | Compugen Names David Silberman CFO | MT |
09/05 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.43% | 9.39Cr | |
+64.23% | 5.51TCr | |
-2.31% | 4.18TCr | |
+44.36% | 4.02TCr | |
-8.29% | 2.82TCr | |
+11.97% | 2.63TCr | |
-21.16% | 1.89TCr | |
+7.54% | 1.3TCr | |
+27.17% | 1.23TCr | |
+25.72% | 1.22TCr |
- Stock Market
- Equities
- ORMP Stock
- News Oramed Pharmaceuticals Inc.
- Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes